Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.
作者信息
Roberts Kaleigh F, Dahiya Sonika M
机构信息
Division of Neuropathology, Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
出版信息
Neuro Oncol. 2023 Aug 3;25(8):1450-1451. doi: 10.1093/neuonc/noad063.
Abstract
摘要
相似文献
1
Mitotic index is (still) important for grading isocitrate dehydrogenase (IDH)-mutant astrocytoma.有丝分裂指数对于异柠檬酸脱氢酶（IDH）突变型星形细胞瘤的分级（仍然）很重要。
Neuro Oncol. 2023 Aug 3;25(8):1450-1451. doi: 10.1093/neuonc/noad063.
2
Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.有丝分裂计数对 IDH 突变型星形细胞瘤具有预后意义，而 CDKN2A/B 杂合缺失则不然。EORTC 试验 26053（CATNON）和 EORTC 试验 22033-26033 共识小组审查结果。
Neuro Oncol. 2023 Aug 3;25(8):1443-1449. doi: 10.1093/neuonc/noac282.
3
Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma.CDKN2A/B 纯合缺失在异柠檬酸脱氢酶突变星形细胞瘤中的转化意义。
Neuro Oncol. 2023 Jan 5;25(1):28-36. doi: 10.1093/neuonc/noac205.
4
Editorial for "Preoperative Discrimination of CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytoma: A Deep Learning-Based Radiomics Model Using MRI".《异柠檬酸脱氢酶突变型星形细胞瘤中CDKN2A/B纯合缺失状态的术前鉴别：基于深度学习的MRI放射组学模型》社论
J Magn Reson Imaging. 2024 May;59(5):1665-1666. doi: 10.1002/jmri.28846. Epub 2023 Jun 12.
5
A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.一种结合组织学分级与CDKN2A纯合及半合子缺失的新型分级系统，用于预测IDH突变型星形细胞瘤的预后。
J Neuropathol Exp Neurol. 2024 Jan 19;83(2):125-130. doi: 10.1093/jnen/nlad112.
6
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.CDKN2A 纯合缺失是弥漫性恶性 IDH 突变型神经胶质瘤的一个强烈不良预后因素。
Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.
7
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.新型改良的 IDH 突变型星形细胞瘤分级系统。
Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.
8
Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.有丝分裂指数阈值不能预测 IDH 突变型星形细胞瘤的临床结局。
J Neuropathol Exp Neurol. 2019 Nov 1;78(11):1002-1010. doi: 10.1093/jnen/nlz082.
9
Medical Statistics Unlock the Gateway to Further Research: Using Deep Learning to Predict CDKN2A/B Homozygous Deletion in Isocitrate Dehydrogenase-Mutant Astrocytoma.医学统计学：开启进一步研究之门——利用深度学习预测异柠檬酸脱氢酶突变型星形细胞瘤中的CDKN2A/B纯合缺失
Korean J Radiol. 2023 Dec;24(12):1303-1305. doi: 10.3348/kjr.2023.0925.
10
A novel MRI-based deep learning networks combined with attention mechanism for predicting CDKN2A/B homozygous deletion status in IDH-mutant astrocytoma.一种新型基于 MRI 的深度学习网络结合注意力机制，用于预测 IDH 突变型星形细胞瘤中 CDKN2A/B 纯合缺失状态。
Eur Radiol. 2024 Jan;34(1):391-399. doi: 10.1007/s00330-023-09944-y. Epub 2023 Aug 8.
引用本文的文献
1
Practical Application of Deep Learning in Diagnostic Neuropathology-Reimagining a Histological Asset in the Era of Precision Medicine.深度学习在诊断神经病理学中的实际应用——在精准医学时代重塑一种组织学资源
Cancers (Basel). 2024 May 23;16(11):1976. doi: 10.3390/cancers16111976.
本文引用的文献
1
Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033.有丝分裂计数对 IDH 突变型星形细胞瘤具有预后意义，而 CDKN2A/B 杂合缺失则不然。EORTC 试验 26053（CATNON）和 EORTC 试验 22033-26033 共识小组审查结果。
Neuro Oncol. 2023 Aug 3;25(8):1443-1449. doi: 10.1093/neuonc/noac282.
2
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
3
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.CDKN2A 纯合缺失是弥漫性恶性 IDH 突变型神经胶质瘤的一个强烈不良预后因素。
Neuro Oncol. 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124.
4
IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.IDH 突变型低级别（WHO 分级 II/III）星形细胞瘤可通过 CDKN2A、CDK4 和 PDGFRA 拷贝数改变进行风险分层。
Brain Pathol. 2020 May;30(3):541-553. doi: 10.1111/bpa.12801. Epub 2019 Dec 3.
5
Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma.有丝分裂指数阈值不能预测 IDH 突变型星形细胞瘤的临床结局。
J Neuropathol Exp Neurol. 2019 Nov 1;78(11):1002-1010. doi: 10.1093/jnen/nlz082.
6
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.新型改良的 IDH 突变型星形细胞瘤分级系统。
Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.
7
Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas.Ki-67增殖指数而非有丝分裂阈值整合了低级别胶质瘤的分子预后分层。
Oncotarget. 2016 Apr 19;7(16):21190-8. doi: 10.18632/oncotarget.8498.
8
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.异柠檬酸脱氢酶（IDH）突变状态以及世界卫生组织（WHO）分级和有丝分裂指数在II-III级弥漫性胶质瘤总生存中的作用。
Acta Neuropathol. 2015 Apr;129(4):585-96. doi: 10.1007/s00401-015-1398-z. Epub 2015 Feb 21.
9
Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.使用有丝分裂标记物磷酸化组蛋白H3评估低级别和中级浸润性星形细胞瘤的有丝分裂指数及其预后意义。
Am J Surg Pathol. 2006 May;30(5):657-64. doi: 10.1097/01.pas.0000202048.28203.25.
10
Grading of astrocytomas. A simple and reproducible method.星形细胞瘤的分级。一种简单且可重复的方法。
Cancer. 1988 Nov 15;62(10):2152-65. doi: 10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t.
Zotero 插件